nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—esophageal cancer	0.306	0.54	CbGaD
Lenalidomide—ABCB1—esophageal cancer	0.26	0.46	CbGaD
Lenalidomide—PTGS2—Cisplatin—esophageal cancer	0.0629	0.648	CbGbCtD
Lenalidomide—ABCB1—Cisplatin—esophageal cancer	0.0208	0.214	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—esophageal cancer	0.0135	0.139	CbGbCtD
Lenalidomide—CDH5—epithelium—esophageal cancer	0.00563	0.0995	CbGeAlD
Lenalidomide—CDH5—bronchus—esophageal cancer	0.00554	0.098	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—esophageal cancer	0.00542	0.0958	CbGeAlD
Lenalidomide—CDH5—trachea—esophageal cancer	0.00498	0.088	CbGeAlD
Lenalidomide—TNFSF11—lung—esophageal cancer	0.00475	0.084	CbGeAlD
Lenalidomide—CDH5—lung—esophageal cancer	0.00358	0.0632	CbGeAlD
Lenalidomide—CRBN—bronchus—esophageal cancer	0.00352	0.0622	CbGeAlD
Lenalidomide—TNFSF11—lymph node—esophageal cancer	0.00325	0.0575	CbGeAlD
Lenalidomide—CRBN—trachea—esophageal cancer	0.00316	0.0559	CbGeAlD
Lenalidomide—CRBN—digestive system—esophageal cancer	0.00272	0.0481	CbGeAlD
Lenalidomide—CDH5—lymph node—esophageal cancer	0.00245	0.0432	CbGeAlD
Lenalidomide—CRBN—lung—esophageal cancer	0.00227	0.0401	CbGeAlD
Lenalidomide—CRBN—lymph node—esophageal cancer	0.00155	0.0275	CbGeAlD
Lenalidomide—Thalidomide—PTGS1—esophageal cancer	0.00154	0.311	CrCbGaD
Lenalidomide—Pomalidomide—PTGS2—esophageal cancer	0.00136	0.276	CrCbGaD
Lenalidomide—Pomalidomide—ABCB1—esophageal cancer	0.00116	0.235	CrCbGaD
Lenalidomide—PTGS2—epithelium—esophageal cancer	0.000974	0.0172	CbGeAlD
Lenalidomide—PTGS2—bronchus—esophageal cancer	0.000959	0.0169	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—esophageal cancer	0.000938	0.0166	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—esophageal cancer	0.00088	0.178	CrCbGaD
Lenalidomide—PTGS2—trachea—esophageal cancer	0.000861	0.0152	CbGeAlD
Lenalidomide—PTGS2—digestive system—esophageal cancer	0.000741	0.0131	CbGeAlD
Lenalidomide—PTGS2—lung—esophageal cancer	0.000619	0.0109	CbGeAlD
Lenalidomide—ABCB1—epithelium—esophageal cancer	0.000602	0.0106	CbGeAlD
Lenalidomide—ABCB1—trachea—esophageal cancer	0.000533	0.00941	CbGeAlD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000506	0.00542	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CA1—esophageal cancer	0.000499	0.00535	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—esophageal cancer	0.000484	0.00518	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000481	0.00515	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000481	0.00515	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000473	0.00507	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000464	0.00497	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GDI2—esophageal cancer	0.000463	0.00496	CbGpPWpGaD
Lenalidomide—ABCB1—digestive system—esophageal cancer	0.000458	0.0081	CbGeAlD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000451	0.00483	CbGpPWpGaD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.00043	0.00461	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—esophageal cancer	0.000423	0.00748	CbGeAlD
Lenalidomide—PTGS2—S1P1 pathway—KDR—esophageal cancer	0.00042	0.0045	CbGpPWpGaD
Lenalidomide—ABCB1—lung—esophageal cancer	0.000383	0.00676	CbGeAlD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000378	0.00405	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000354	0.00379	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PIK3CA—esophageal cancer	0.000336	0.00361	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KMT2D—esophageal cancer	0.000334	0.00358	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—FKBP1A—esophageal cancer	0.000331	0.00354	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000322	0.00345	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PIK3CA—esophageal cancer	0.000318	0.0034	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.000313	0.00335	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—BCL2—esophageal cancer	0.00031	0.00332	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000301	0.00322	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ADCYAP1—esophageal cancer	0.000298	0.00319	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—PIK3CA—esophageal cancer	0.000288	0.00309	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—WWOX—esophageal cancer	0.000273	0.00292	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—esophageal cancer	0.000262	0.00462	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—FKBP1A—esophageal cancer	0.000259	0.00278	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—WIF1—esophageal cancer	0.000253	0.00272	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000245	0.00263	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CSNK1A1—esophageal cancer	0.000234	0.00251	CbGpPWpGaD
Lenalidomide—Arrhythmia—Cisplatin—esophageal cancer	0.000231	0.00127	CcSEcCtD
Lenalidomide—Bronchitis—Capecitabine—esophageal cancer	0.000229	0.00126	CcSEcCtD
Lenalidomide—Alopecia—Cisplatin—esophageal cancer	0.000229	0.00126	CcSEcCtD
Lenalidomide—Abdominal discomfort—Capecitabine—esophageal cancer	0.000228	0.00126	CcSEcCtD
Lenalidomide—Hepatic failure—Methotrexate—esophageal cancer	0.000228	0.00126	CcSEcCtD
Lenalidomide—Pancytopenia—Capecitabine—esophageal cancer	0.000226	0.00124	CcSEcCtD
Lenalidomide—Malnutrition—Cisplatin—esophageal cancer	0.000225	0.00124	CcSEcCtD
Lenalidomide—Erythema—Cisplatin—esophageal cancer	0.000225	0.00124	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000225	0.00241	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000225	0.00241	CbGpPWpGaD
Lenalidomide—Dysuria—Capecitabine—esophageal cancer	0.000223	0.00122	CcSEcCtD
Lenalidomide—Neutropenia—Capecitabine—esophageal cancer	0.000223	0.00122	CcSEcCtD
Lenalidomide—Renal failure acute—Methotrexate—esophageal cancer	0.000222	0.00122	CcSEcCtD
Lenalidomide—Flatulence—Cisplatin—esophageal cancer	0.000222	0.00122	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000221	0.00122	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PFN1—esophageal cancer	0.000219	0.00234	CbGpPWpGaD
Lenalidomide—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000217	0.0012	CcSEcCtD
Lenalidomide—Weight increased—Capecitabine—esophageal cancer	0.000217	0.00119	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000217	0.00232	CbGpPWpGaD
Lenalidomide—Visual disturbance—Methotrexate—esophageal cancer	0.000217	0.00119	CcSEcCtD
Lenalidomide—Muscle spasms—Cisplatin—esophageal cancer	0.000216	0.00119	CcSEcCtD
Lenalidomide—Weight decreased—Capecitabine—esophageal cancer	0.000216	0.00118	CcSEcCtD
Lenalidomide—Hyperglycaemia—Capecitabine—esophageal cancer	0.000215	0.00118	CcSEcCtD
Lenalidomide—Pneumonia—Capecitabine—esophageal cancer	0.000214	0.00117	CcSEcCtD
Lenalidomide—Infestation NOS—Capecitabine—esophageal cancer	0.000212	0.00117	CcSEcCtD
Lenalidomide—Infestation—Capecitabine—esophageal cancer	0.000212	0.00117	CcSEcCtD
Lenalidomide—Vision blurred—Cisplatin—esophageal cancer	0.000212	0.00117	CcSEcCtD
Lenalidomide—Depression—Capecitabine—esophageal cancer	0.000212	0.00116	CcSEcCtD
Lenalidomide—Tremor—Cisplatin—esophageal cancer	0.000211	0.00116	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000211	0.00116	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000209	0.00115	CcSEcCtD
Lenalidomide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000209	0.00115	CcSEcCtD
Lenalidomide—Lethargy—Methotrexate—esophageal cancer	0.000209	0.00115	CcSEcCtD
Lenalidomide—Ill-defined disorder—Cisplatin—esophageal cancer	0.000209	0.00115	CcSEcCtD
Lenalidomide—Renal failure—Capecitabine—esophageal cancer	0.000209	0.00115	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000208	0.00114	CcSEcCtD
Lenalidomide—Myocardial infarction—Capecitabine—esophageal cancer	0.000208	0.00114	CcSEcCtD
Lenalidomide—Anaemia—Cisplatin—esophageal cancer	0.000208	0.00114	CcSEcCtD
Lenalidomide—Stomatitis—Capecitabine—esophageal cancer	0.000207	0.00114	CcSEcCtD
Lenalidomide—Urinary tract infection—Capecitabine—esophageal cancer	0.000206	0.00113	CcSEcCtD
Lenalidomide—Conjunctivitis—Capecitabine—esophageal cancer	0.000206	0.00113	CcSEcCtD
Lenalidomide—Osteoarthritis—Methotrexate—esophageal cancer	0.000205	0.00113	CcSEcCtD
Lenalidomide—Malaise—Cisplatin—esophageal cancer	0.000203	0.00112	CcSEcCtD
Lenalidomide—Haematuria—Capecitabine—esophageal cancer	0.000203	0.00111	CcSEcCtD
Lenalidomide—Leukopenia—Cisplatin—esophageal cancer	0.000202	0.00111	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000201	0.0011	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000201	0.00215	CbGpPWpGaD
Lenalidomide—Epistaxis—Capecitabine—esophageal cancer	0.0002	0.0011	CcSEcCtD
Lenalidomide—Agranulocytosis—Capecitabine—esophageal cancer	0.000198	0.00109	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ELMO1—esophageal cancer	0.000197	0.00211	CbGpPWpGaD
Lenalidomide—Mood swings—Methotrexate—esophageal cancer	0.000194	0.00107	CcSEcCtD
Lenalidomide—Bradycardia—Capecitabine—esophageal cancer	0.000194	0.00107	CcSEcCtD
Lenalidomide—Ataxia—Methotrexate—esophageal cancer	0.000193	0.00106	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—AKAP13—esophageal cancer	0.000192	0.00206	CbGpPWpGaD
Lenalidomide—Myalgia—Cisplatin—esophageal cancer	0.000192	0.00105	CcSEcCtD
Lenalidomide—Haemoglobin—Capecitabine—esophageal cancer	0.000192	0.00105	CcSEcCtD
Lenalidomide—Rhinitis—Capecitabine—esophageal cancer	0.000191	0.00105	CcSEcCtD
Lenalidomide—Anxiety—Cisplatin—esophageal cancer	0.000191	0.00105	CcSEcCtD
Lenalidomide—Haemorrhage—Capecitabine—esophageal cancer	0.000191	0.00105	CcSEcCtD
Lenalidomide—Hepatitis—Capecitabine—esophageal cancer	0.000191	0.00105	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00019	0.00105	CcSEcCtD
Lenalidomide—Hypoaesthesia—Capecitabine—esophageal cancer	0.00019	0.00104	CcSEcCtD
Lenalidomide—Liver function test abnormal—Methotrexate—esophageal cancer	0.000189	0.00104	CcSEcCtD
Lenalidomide—Discomfort—Cisplatin—esophageal cancer	0.000189	0.00104	CcSEcCtD
Lenalidomide—Pharyngitis—Capecitabine—esophageal cancer	0.000189	0.00104	CcSEcCtD
Lenalidomide—Urinary tract disorder—Capecitabine—esophageal cancer	0.000188	0.00104	CcSEcCtD
Lenalidomide—Oedema peripheral—Capecitabine—esophageal cancer	0.000188	0.00103	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.000188	0.00201	CbGpPWpGaD
Lenalidomide—Connective tissue disorder—Capecitabine—esophageal cancer	0.000187	0.00103	CcSEcCtD
Lenalidomide—Urethral disorder—Capecitabine—esophageal cancer	0.000187	0.00103	CcSEcCtD
Lenalidomide—Breast disorder—Methotrexate—esophageal cancer	0.000185	0.00102	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000185	0.00102	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.000184	0.00197	CbGpPWpGaD
Lenalidomide—Oedema—Cisplatin—esophageal cancer	0.000184	0.00101	CcSEcCtD
Lenalidomide—Visual impairment—Capecitabine—esophageal cancer	0.000184	0.00101	CcSEcCtD
Lenalidomide—Infection—Cisplatin—esophageal cancer	0.000183	0.001	CcSEcCtD
Lenalidomide—Erythema multiforme—Capecitabine—esophageal cancer	0.00018	0.000991	CcSEcCtD
Lenalidomide—Nervous system disorder—Cisplatin—esophageal cancer	0.00018	0.000991	CcSEcCtD
Lenalidomide—Thrombocytopenia—Cisplatin—esophageal cancer	0.00018	0.000989	CcSEcCtD
Lenalidomide—Tachycardia—Cisplatin—esophageal cancer	0.000179	0.000986	CcSEcCtD
Lenalidomide—Skin disorder—Cisplatin—esophageal cancer	0.000178	0.000981	CcSEcCtD
Lenalidomide—Eye disorder—Capecitabine—esophageal cancer	0.000178	0.00098	CcSEcCtD
Lenalidomide—Tinnitus—Capecitabine—esophageal cancer	0.000178	0.000977	CcSEcCtD
Lenalidomide—Hyperhidrosis—Cisplatin—esophageal cancer	0.000178	0.000977	CcSEcCtD
Lenalidomide—Asthma—Methotrexate—esophageal cancer	0.000177	0.000975	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000177	0.0019	CbGpPWpGaD
Lenalidomide—Cardiac disorder—Capecitabine—esophageal cancer	0.000177	0.000973	CcSEcCtD
Lenalidomide—Flushing—Capecitabine—esophageal cancer	0.000177	0.000973	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000176	0.00189	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDE4D—esophageal cancer	0.000176	0.00188	CbGpPWpGaD
Lenalidomide—Anorexia—Cisplatin—esophageal cancer	0.000175	0.000963	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000175	0.00187	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000175	0.00187	CbGpPWpGaD
Lenalidomide—Pancreatitis—Methotrexate—esophageal cancer	0.000174	0.000956	CcSEcCtD
Lenalidomide—Angiopathy—Capecitabine—esophageal cancer	0.000173	0.000951	CcSEcCtD
Lenalidomide—Immune system disorder—Capecitabine—esophageal cancer	0.000172	0.000947	CcSEcCtD
Lenalidomide—Mediastinal disorder—Capecitabine—esophageal cancer	0.000172	0.000945	CcSEcCtD
Lenalidomide—Hypotension—Cisplatin—esophageal cancer	0.000172	0.000944	CcSEcCtD
Lenalidomide—Chills—Capecitabine—esophageal cancer	0.000171	0.000941	CcSEcCtD
Lenalidomide—Arrhythmia—Capecitabine—esophageal cancer	0.00017	0.000936	CcSEcCtD
Lenalidomide—Abdominal discomfort—Methotrexate—esophageal cancer	0.00017	0.000935	CcSEcCtD
Lenalidomide—Alopecia—Capecitabine—esophageal cancer	0.000168	0.000926	CcSEcCtD
Lenalidomide—Pancytopenia—Methotrexate—esophageal cancer	0.000168	0.000926	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000167	0.00092	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—GNG7—esophageal cancer	0.000167	0.00179	CbGpPWpGaD
Lenalidomide—Mental disorder—Capecitabine—esophageal cancer	0.000167	0.000918	CcSEcCtD
Lenalidomide—Malnutrition—Capecitabine—esophageal cancer	0.000166	0.000912	CcSEcCtD
Lenalidomide—Erythema—Capecitabine—esophageal cancer	0.000166	0.000912	CcSEcCtD
Lenalidomide—Dysuria—Methotrexate—esophageal cancer	0.000166	0.000912	CcSEcCtD
Lenalidomide—Neutropenia—Methotrexate—esophageal cancer	0.000166	0.000912	CcSEcCtD
Lenalidomide—Paraesthesia—Cisplatin—esophageal cancer	0.000165	0.000907	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000165	0.000906	CcSEcCtD
Lenalidomide—Dyspnoea—Cisplatin—esophageal cancer	0.000164	0.000901	CcSEcCtD
Lenalidomide—Flatulence—Capecitabine—esophageal cancer	0.000164	0.000899	CcSEcCtD
Lenalidomide—Erectile dysfunction—Methotrexate—esophageal cancer	0.000163	0.000898	CcSEcCtD
Lenalidomide—Dysgeusia—Capecitabine—esophageal cancer	0.000163	0.000894	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000162	0.00089	CcSEcCtD
Lenalidomide—Back pain—Capecitabine—esophageal cancer	0.000161	0.000883	CcSEcCtD
Lenalidomide—Decreased appetite—Cisplatin—esophageal cancer	0.00016	0.000878	CcSEcCtD
Lenalidomide—Muscle spasms—Capecitabine—esophageal cancer	0.00016	0.000877	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00016	0.00171	CbGpPWpGaD
Lenalidomide—Pneumonia—Methotrexate—esophageal cancer	0.000159	0.000874	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000159	0.000872	CcSEcCtD
Lenalidomide—Infestation—Methotrexate—esophageal cancer	0.000158	0.000869	CcSEcCtD
Lenalidomide—Infestation NOS—Methotrexate—esophageal cancer	0.000158	0.000869	CcSEcCtD
Lenalidomide—Depression—Methotrexate—esophageal cancer	0.000158	0.000867	CcSEcCtD
Lenalidomide—Pain—Cisplatin—esophageal cancer	0.000157	0.000864	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000157	0.000862	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—XIAP—esophageal cancer	0.000157	0.00168	CbGpPWpGaD
Lenalidomide—Vision blurred—Capecitabine—esophageal cancer	0.000156	0.00086	CcSEcCtD
Lenalidomide—Tremor—Capecitabine—esophageal cancer	0.000156	0.000855	CcSEcCtD
Lenalidomide—Renal failure—Methotrexate—esophageal cancer	0.000155	0.000854	CcSEcCtD
Lenalidomide—Stomatitis—Methotrexate—esophageal cancer	0.000154	0.000847	CcSEcCtD
Lenalidomide—Ill-defined disorder—Capecitabine—esophageal cancer	0.000154	0.000847	CcSEcCtD
Lenalidomide—Conjunctivitis—Methotrexate—esophageal cancer	0.000154	0.000845	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000154	0.00165	CbGpPWpGaD
Lenalidomide—Anaemia—Capecitabine—esophageal cancer	0.000153	0.000843	CcSEcCtD
Lenalidomide—Sweating—Methotrexate—esophageal cancer	0.000152	0.000833	CcSEcCtD
Lenalidomide—Feeling abnormal—Cisplatin—esophageal cancer	0.000151	0.000832	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—esophageal cancer	0.000151	0.000829	CcSEcCtD
Lenalidomide—Malaise—Capecitabine—esophageal cancer	0.00015	0.000823	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00015	0.000822	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—esophageal cancer	0.000149	0.00082	CcSEcCtD
Lenalidomide—Vertigo—Capecitabine—esophageal cancer	0.000149	0.00082	CcSEcCtD
Lenalidomide—Syncope—Capecitabine—esophageal cancer	0.000149	0.000818	CcSEcCtD
Lenalidomide—Leukopenia—Capecitabine—esophageal cancer	0.000149	0.000817	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CTNNA1—esophageal cancer	0.000148	0.00159	CbGpPWpGaD
Lenalidomide—Agranulocytosis—Methotrexate—esophageal cancer	0.000148	0.000811	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL2—esophageal cancer	0.000147	0.00158	CbGpPWpGaD
Lenalidomide—Palpitations—Capecitabine—esophageal cancer	0.000147	0.000806	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.000147	0.00157	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Capecitabine—esophageal cancer	0.000146	0.000802	CcSEcCtD
Lenalidomide—Body temperature increased—Cisplatin—esophageal cancer	0.000145	0.000799	CcSEcCtD
Lenalidomide—Cough—Capecitabine—esophageal cancer	0.000145	0.000796	CcSEcCtD
Lenalidomide—Hypertension—Capecitabine—esophageal cancer	0.000143	0.000788	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—esophageal cancer	0.000143	0.000784	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—esophageal cancer	0.000142	0.00078	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—esophageal cancer	0.000142	0.00078	CcSEcCtD
Lenalidomide—Arthralgia—Capecitabine—esophageal cancer	0.000141	0.000777	CcSEcCtD
Lenalidomide—Chest pain—Capecitabine—esophageal cancer	0.000141	0.000777	CcSEcCtD
Lenalidomide—Myalgia—Capecitabine—esophageal cancer	0.000141	0.000777	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—esophageal cancer	0.000141	0.000774	CcSEcCtD
Lenalidomide—Anxiety—Capecitabine—esophageal cancer	0.000141	0.000774	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.000141	0.00151	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00014	0.000771	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00014	0.000771	CcSEcCtD
Lenalidomide—Discomfort—Capecitabine—esophageal cancer	0.00014	0.000768	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—esophageal cancer	0.000139	0.000765	CcSEcCtD
Lenalidomide—Dry mouth—Capecitabine—esophageal cancer	0.000138	0.00076	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PSME1—esophageal cancer	0.000138	0.00147	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PSME2—esophageal cancer	0.000138	0.00147	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ANXA1—esophageal cancer	0.000137	0.00147	CbGpPWpGaD
Lenalidomide—Visual impairment—Methotrexate—esophageal cancer	0.000137	0.000752	CcSEcCtD
Lenalidomide—Confusional state—Capecitabine—esophageal cancer	0.000137	0.000751	CcSEcCtD
Lenalidomide—Oedema—Capecitabine—esophageal cancer	0.000135	0.000745	CcSEcCtD
Lenalidomide—Hypersensitivity—Cisplatin—esophageal cancer	0.000135	0.000744	CcSEcCtD
Lenalidomide—Infection—Capecitabine—esophageal cancer	0.000135	0.00074	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—esophageal cancer	0.000134	0.000738	CcSEcCtD
Lenalidomide—Shock—Capecitabine—esophageal cancer	0.000133	0.000733	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SST—esophageal cancer	0.000133	0.00143	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Capecitabine—esophageal cancer	0.000133	0.00073	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—esophageal cancer	0.000133	0.000729	CcSEcCtD
Lenalidomide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000133	0.000729	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—esophageal cancer	0.000132	0.000728	CcSEcCtD
Lenalidomide—Tachycardia—Capecitabine—esophageal cancer	0.000132	0.000727	CcSEcCtD
Lenalidomide—Asthenia—Cisplatin—esophageal cancer	0.000132	0.000725	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—esophageal cancer	0.000132	0.000724	CcSEcCtD
Lenalidomide—Skin disorder—Capecitabine—esophageal cancer	0.000132	0.000723	CcSEcCtD
Lenalidomide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000131	0.00072	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—GHRL—esophageal cancer	0.00013	0.00139	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOTCH3—esophageal cancer	0.00013	0.00139	CbGpPWpGaD
Lenalidomide—Anorexia—Capecitabine—esophageal cancer	0.000129	0.00071	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—esophageal cancer	0.000129	0.000708	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—esophageal cancer	0.000128	0.000705	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—esophageal cancer	0.000128	0.000703	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—FBXW7—esophageal cancer	0.000128	0.00137	CbGpPWpGaD
Lenalidomide—Chills—Methotrexate—esophageal cancer	0.000127	0.0007	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000127	0.00136	CbGpPWpGaD
Lenalidomide—Hypotension—Capecitabine—esophageal cancer	0.000127	0.000696	CcSEcCtD
Lenalidomide—Diarrhoea—Cisplatin—esophageal cancer	0.000126	0.000691	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—esophageal cancer	0.000125	0.00069	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—esophageal cancer	0.000124	0.000684	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000124	0.00133	CbGpPWpGaD
Lenalidomide—Erythema—Methotrexate—esophageal cancer	0.000124	0.000679	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—esophageal cancer	0.000124	0.000679	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000123	0.000678	CcSEcCtD
Lenalidomide—Insomnia—Capecitabine—esophageal cancer	0.000123	0.000674	CcSEcCtD
Lenalidomide—Paraesthesia—Capecitabine—esophageal cancer	0.000122	0.000669	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—esophageal cancer	0.000121	0.000665	CcSEcCtD
Lenalidomide—Dyspnoea—Capecitabine—esophageal cancer	0.000121	0.000664	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000121	0.00129	CbGpPWpGaD
Lenalidomide—Back pain—Methotrexate—esophageal cancer	0.00012	0.000657	CcSEcCtD
Lenalidomide—Dyspepsia—Capecitabine—esophageal cancer	0.000119	0.000656	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000119	0.00127	CbGpPWpGaD
Lenalidomide—Decreased appetite—Capecitabine—esophageal cancer	0.000118	0.000647	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000117	0.000643	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—esophageal cancer	0.000117	0.000642	CcSEcCtD
Lenalidomide—Fatigue—Capecitabine—esophageal cancer	0.000117	0.000642	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—esophageal cancer	0.000116	0.00064	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NOTCH2—esophageal cancer	0.000116	0.00125	CbGpPWpGaD
Lenalidomide—Rash—Cisplatin—esophageal cancer	0.000116	0.000637	CcSEcCtD
Lenalidomide—Constipation—Capecitabine—esophageal cancer	0.000116	0.000637	CcSEcCtD
Lenalidomide—Pain—Capecitabine—esophageal cancer	0.000116	0.000637	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—esophageal cancer	0.000116	0.000636	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.000115	0.00123	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Methotrexate—esophageal cancer	0.000115	0.00063	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—esophageal cancer	0.000114	0.000628	CcSEcCtD
Lenalidomide—Feeling abnormal—Capecitabine—esophageal cancer	0.000112	0.000614	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—esophageal cancer	0.000111	0.000613	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—esophageal cancer	0.000111	0.00061	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000111	0.000609	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—esophageal cancer	0.000111	0.000608	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000109	0.00117	CbGpPWpGaD
Lenalidomide—Nausea—Cisplatin—esophageal cancer	0.000109	0.0006	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000109	0.00116	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000108	0.00116	CbGpPWpGaD
Lenalidomide—Cough—Methotrexate—esophageal cancer	0.000108	0.000593	CcSEcCtD
Lenalidomide—Urticaria—Capecitabine—esophageal cancer	0.000108	0.000592	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.000107	0.00115	CbGpPWpGaD
Lenalidomide—Abdominal pain—Capecitabine—esophageal cancer	0.000107	0.000589	CcSEcCtD
Lenalidomide—Body temperature increased—Capecitabine—esophageal cancer	0.000107	0.000589	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—esophageal cancer	0.000105	0.000578	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—esophageal cancer	0.000105	0.000578	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—esophageal cancer	0.000105	0.000578	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000105	0.00113	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000105	0.00112	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000104	0.000574	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—esophageal cancer	0.000104	0.000571	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000103	0.00111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFBR2—esophageal cancer	0.000103	0.00111	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000103	0.0011	CbGpPWpGaD
Lenalidomide—Confusional state—Methotrexate—esophageal cancer	0.000102	0.000559	CcSEcCtD
Lenalidomide—Infection—Methotrexate—esophageal cancer	0.0001	0.000551	CcSEcCtD
Lenalidomide—Hypersensitivity—Capecitabine—esophageal cancer	9.98e-05	0.000549	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—esophageal cancer	9.89e-05	0.000544	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—esophageal cancer	9.87e-05	0.000543	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—esophageal cancer	9.79e-05	0.000538	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SMAD4—esophageal cancer	9.77e-05	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	9.75e-05	0.00105	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Methotrexate—esophageal cancer	9.75e-05	0.000536	CcSEcCtD
Lenalidomide—Asthenia—Capecitabine—esophageal cancer	9.72e-05	0.000534	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—esophageal cancer	9.61e-05	0.000528	CcSEcCtD
Lenalidomide—Pruritus—Capecitabine—esophageal cancer	9.58e-05	0.000527	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	9.58e-05	0.00103	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	9.43e-05	0.00101	CbGpPWpGaD
Lenalidomide—Hypotension—Methotrexate—esophageal cancer	9.42e-05	0.000518	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	9.4e-05	0.00101	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	9.28e-05	0.000994	CbGpPWpGaD
Lenalidomide—Diarrhoea—Capecitabine—esophageal cancer	9.27e-05	0.00051	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.19e-05	0.000505	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—esophageal cancer	9.12e-05	0.000501	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—esophageal cancer	9.05e-05	0.000498	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—esophageal cancer	8.99e-05	0.000494	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—esophageal cancer	8.96e-05	0.000493	CcSEcCtD
Lenalidomide—Dizziness—Capecitabine—esophageal cancer	8.96e-05	0.000492	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—esophageal cancer	8.88e-05	0.000488	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—esophageal cancer	8.77e-05	0.000482	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	8.76e-05	0.000938	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.71e-05	0.000479	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—esophageal cancer	8.69e-05	0.000478	CcSEcCtD
Lenalidomide—Pain—Methotrexate—esophageal cancer	8.62e-05	0.000474	CcSEcCtD
Lenalidomide—Vomiting—Capecitabine—esophageal cancer	8.61e-05	0.000473	CcSEcCtD
Lenalidomide—Rash—Capecitabine—esophageal cancer	8.54e-05	0.00047	CcSEcCtD
Lenalidomide—Dermatitis—Capecitabine—esophageal cancer	8.53e-05	0.000469	CcSEcCtD
Lenalidomide—Headache—Capecitabine—esophageal cancer	8.49e-05	0.000467	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	8.48e-05	0.000909	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	8.48e-05	0.000909	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	8.42e-05	0.000902	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Methotrexate—esophageal cancer	8.31e-05	0.000457	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	8.3e-05	0.000889	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Methotrexate—esophageal cancer	8.25e-05	0.000453	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—CASP8—esophageal cancer	8.18e-05	0.000876	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	8.09e-05	0.000867	CbGpPWpGaD
Lenalidomide—Nausea—Capecitabine—esophageal cancer	8.05e-05	0.000442	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.02e-05	0.00086	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—esophageal cancer	8.01e-05	0.00044	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HIF1A—esophageal cancer	8e-05	0.000857	CbGpPWpGaD
Lenalidomide—Body temperature increased—Methotrexate—esophageal cancer	7.97e-05	0.000438	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—esophageal cancer	7.97e-05	0.000438	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	7.83e-05	0.000839	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	7.7e-05	0.000825	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KDR—esophageal cancer	7.65e-05	0.00082	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	7.45e-05	0.000798	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—esophageal cancer	7.43e-05	0.000408	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	7.32e-05	0.000785	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.3e-05	0.000782	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	7.28e-05	0.00078	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—esophageal cancer	7.24e-05	0.000398	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NOTCH1—esophageal cancer	7.2e-05	0.000772	CbGpPWpGaD
Lenalidomide—Pruritus—Methotrexate—esophageal cancer	7.13e-05	0.000392	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	7.08e-05	0.000759	CbGpPWpGaD
Lenalidomide—Diarrhoea—Methotrexate—esophageal cancer	6.9e-05	0.000379	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	6.84e-05	0.000733	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SLC52A3—esophageal cancer	6.75e-05	0.000724	CbGpPWpGaD
Lenalidomide—Dizziness—Methotrexate—esophageal cancer	6.67e-05	0.000367	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CREBBP—esophageal cancer	6.53e-05	0.0007	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	6.49e-05	0.000695	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	6.49e-05	0.000695	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KMT2D—esophageal cancer	6.44e-05	0.00069	CbGpPWpGaD
Lenalidomide—Vomiting—Methotrexate—esophageal cancer	6.41e-05	0.000352	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	6.4e-05	0.000686	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.37e-05	0.000682	CbGpPWpGaD
Lenalidomide—Rash—Methotrexate—esophageal cancer	6.36e-05	0.00035	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—esophageal cancer	6.35e-05	0.000349	CcSEcCtD
Lenalidomide—Headache—Methotrexate—esophageal cancer	6.32e-05	0.000347	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	6.21e-05	0.000665	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	6.19e-05	0.000663	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	6.16e-05	0.00066	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.01e-05	0.000644	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—esophageal cancer	5.99e-05	0.000329	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	5.93e-05	0.000636	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	5.93e-05	0.000636	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—esophageal cancer	5.85e-05	0.000627	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	5.69e-05	0.00061	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	5.69e-05	0.000609	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	5.67e-05	0.000607	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BLVRB—esophageal cancer	5.66e-05	0.000606	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC52A3—esophageal cancer	5.66e-05	0.000606	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—esophageal cancer	5.47e-05	0.000586	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.06e-05	0.000542	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FKBP1A—esophageal cancer	5e-05	0.000535	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	4.94e-05	0.00053	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.89e-05	0.000523	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DOCK2—esophageal cancer	4.88e-05	0.000523	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WIF1—esophageal cancer	4.88e-05	0.000523	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	4.84e-05	0.000518	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—esophageal cancer	4.83e-05	0.000518	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC10A2—esophageal cancer	4.81e-05	0.000515	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA1—esophageal cancer	4.81e-05	0.000515	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.75e-05	0.000509	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—esophageal cancer	4.68e-05	0.000501	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CSNK1A1—esophageal cancer	4.51e-05	0.000483	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	4.5e-05	0.000482	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EP300—esophageal cancer	4.45e-05	0.000477	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CA2—esophageal cancer	4.4e-05	0.000471	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.3e-05	0.000461	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.19e-05	0.000449	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADH7—esophageal cancer	4.09e-05	0.000438	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLCE1—esophageal cancer	4.09e-05	0.000438	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.08e-05	0.000437	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.06e-05	0.000435	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.06e-05	0.000435	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.04e-05	0.000433	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.04e-05	0.000432	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.02e-05	0.00043	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BLVRB—esophageal cancer	4.01e-05	0.00043	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC52A3—esophageal cancer	4.01e-05	0.00043	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—esophageal cancer	3.88e-05	0.000415	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.86e-05	0.000414	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—esophageal cancer	3.79e-05	0.000406	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ELMO1—esophageal cancer	3.79e-05	0.000406	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TPI1—esophageal cancer	3.7e-05	0.000397	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GSTO1—esophageal cancer	3.7e-05	0.000397	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADH1B—esophageal cancer	3.59e-05	0.000384	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ALDOB—esophageal cancer	3.55e-05	0.00038	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.46e-05	0.000371	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMP—esophageal cancer	3.43e-05	0.000367	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GAPDH—esophageal cancer	3.42e-05	0.000366	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIST1H2BM—esophageal cancer	3.42e-05	0.000366	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA1—esophageal cancer	3.41e-05	0.000365	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC10A2—esophageal cancer	3.41e-05	0.000365	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.36e-05	0.00036	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.36e-05	0.00036	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.33e-05	0.000357	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—esophageal cancer	3.29e-05	0.000353	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.29e-05	0.000352	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.29e-05	0.000352	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALOX15—esophageal cancer	3.25e-05	0.000348	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—esophageal cancer	3.18e-05	0.000341	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CA2—esophageal cancer	3.12e-05	0.000334	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TPI1—esophageal cancer	3.1e-05	0.000332	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTO1—esophageal cancer	3.1e-05	0.000332	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—XIAP—esophageal cancer	3.02e-05	0.000323	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.97e-05	0.000318	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDOB—esophageal cancer	2.97e-05	0.000318	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLCE1—esophageal cancer	2.9e-05	0.000311	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADH7—esophageal cancer	2.9e-05	0.000311	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.88e-05	0.000308	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GAPDH—esophageal cancer	2.86e-05	0.000306	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.86e-05	0.000306	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CRABP1—esophageal cancer	2.83e-05	0.000304	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—B2M—esophageal cancer	2.8e-05	0.000301	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.76e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.74e-05	0.000293	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNG7—esophageal cancer	2.7e-05	0.000289	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO1—esophageal cancer	2.69e-05	0.000288	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSME2—esophageal cancer	2.65e-05	0.000284	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSME1—esophageal cancer	2.65e-05	0.000284	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CALR—esophageal cancer	2.54e-05	0.000272	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADH1B—esophageal cancer	2.54e-05	0.000272	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDH2—esophageal cancer	2.53e-05	0.000271	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.49e-05	0.000266	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FBXW7—esophageal cancer	2.46e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMP—esophageal cancer	2.43e-05	0.00026	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—esophageal cancer	2.4e-05	0.000258	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.38e-05	0.000255	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.38e-05	0.000255	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.37e-05	0.000254	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.36e-05	0.000253	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.33e-05	0.00025	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALOX15—esophageal cancer	2.3e-05	0.000247	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTGS1—esophageal cancer	2.25e-05	0.000241	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO1—esophageal cancer	2.25e-05	0.000241	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSME1—esophageal cancer	2.22e-05	0.000238	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSME2—esophageal cancer	2.22e-05	0.000238	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TPI1—esophageal cancer	2.2e-05	0.000235	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTO1—esophageal cancer	2.2e-05	0.000235	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDOB—esophageal cancer	2.11e-05	0.000226	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GAPDH—esophageal cancer	2.03e-05	0.000217	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.02e-05	0.000217	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CRABP1—esophageal cancer	2.01e-05	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFBR2—esophageal cancer	1.99e-05	0.000213	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.96e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.91e-05	0.000205	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNG7—esophageal cancer	1.91e-05	0.000205	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SMAD4—esophageal cancer	1.88e-05	0.000202	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.8e-05	0.000193	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDH2—esophageal cancer	1.79e-05	0.000192	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—esophageal cancer	1.7e-05	0.000183	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.68e-05	0.00018	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMOX1—esophageal cancer	1.64e-05	0.000176	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.61e-05	0.000173	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS1—esophageal cancer	1.6e-05	0.000171	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO1—esophageal cancer	1.6e-05	0.000171	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.6e-05	0.000171	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—esophageal cancer	1.58e-05	0.000169	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSME1—esophageal cancer	1.57e-05	0.000169	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSME2—esophageal cancer	1.57e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—esophageal cancer	1.54e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—esophageal cancer	1.4e-05	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—esophageal cancer	1.39e-05	0.000149	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.36e-05	0.000145	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.28e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CREBBP—esophageal cancer	1.26e-05	0.000135	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.19e-05	0.000128	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMOX1—esophageal cancer	1.16e-05	0.000125	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—esophageal cancer	1.13e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CREBBP—esophageal cancer	1.05e-05	0.000113	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—esophageal cancer	1.05e-05	0.000113	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—esophageal cancer	9.44e-06	0.000101	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—esophageal cancer	9.01e-06	9.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—esophageal cancer	8.57e-06	9.18e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CREBBP—esophageal cancer	7.47e-06	8.01e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—esophageal cancer	7.47e-06	8e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—esophageal cancer	7.31e-06	7.83e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—esophageal cancer	7.18e-06	7.69e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—esophageal cancer	6.69e-06	7.17e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—esophageal cancer	6.34e-06	6.79e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—esophageal cancer	6.12e-06	6.56e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.31e-06	5.69e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—esophageal cancer	5.09e-06	5.45e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.76e-06	4.03e-05	CbGpPWpGaD
